Severe COVID-19 is frequently associated with thromboembolic complications. Increased
platelet activation and platelet–leukocyte aggregate formation can amplify thrombotic …

Platelets and platelet extracellular vesicles (pEV) are at the crossroads of coagulation and
immunity. Extracellular vesicles are messengers that not only transmit signals between cells …

Coagulation disturbances are major contributors to COVID-19 pathogenicity, but limited data
exist on the involvement of extracellular vesicles (EVs) and residual cells (RCs). Fifty …

Activated platelets and platelet-derived extracellular vesicles (EVs) have emerged as central
players in thromboembolic complications associated with severe coronavirus disease 2019 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent pathogen
responsible for the coronavirus disease 2019 (COVID-19). Since its emergence, the novel …

Severe COVID-19 infections present with cytokine storms, hypercoagulation, and acute
respiratory distress syndrome, with extracellular vesicles (EVs) being involved in …

Abnormal coagulation dynamics, including disseminated intravascular coagulopathy,
pulmonary embolism, venous thromboembolism and risk of thrombosis are often associated …

Background Extracellular vesicles (EVs) are a valuable source of biomarkers and display
the pathophysiological status of various diseases. In COVID-19, EVs have been explored in …

Patients with COVID-19 often have hypoxemia, impaired lung function, and abnormal
imaging manifestations in acute and convalescent stages. Alveolar inflammation, pulmonary …

The authors hypothesized that the cytokine storm described in COVID-19 patients may lead
to consistent cell-based tissue factor (TF)-mediated activation of coagulation, procoagulant …